Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor

Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor

The goal of this clinical trial is to learn about the effects of Docosahexaenoic acid (DHA) in reducing the incidence of premature birth in threatened preterm labor

The main questions it aims to answer are:

• Can DHA supplementation reduce the incidence of premature birth in threatened preterm labor?
• How does DHA supplementation affect pregnancy outcomes? Participants were organized into two groups
• Group 1 (Intervention) Participants will be asked to take a DHA 1000mg per day
• Group 2 (control) Participant will not need to take a DHA

Threatened preterm labor is defined as regular uterine contractions occurring before 37 completed weeks of gestation, without any cervical dilation.

Inclusion Criteria:

• Singleton pregnancy
• Between 24 wk to 34 wk of gestational age
• Pregnant women diagnosed threatened preterm labor (with no cervical change)

Exclusion Criteria:

• Fetal anomalies
• Multiple pregnancy
• Premature rupture of membrane
• Placental disorders: placenta previa, placental abruption
• Fetal growth restriction
• Pregnancy complication: gestational diabetes mellitus, Chronic hypertension
• Allergic reaction to DHA